What is Cymbiotika?
Cymbiotika operates as a sophisticated online platform dedicated to the distribution of premium natural and organic health products. The company distinguishes itself through a curated catalog of supplements designed to address specific physiological needs, including immune support, dermatological health, physical fitness, and stress management. By integrating subscription-based models and strategic partnerships with wellness applications, Cymbiotika has successfully cultivated a loyal customer base of health-conscious individuals. Its market position is defined by a commitment to high-quality, bioavailable ingredients, effectively bridging the gap between traditional supplement retail and modern, data-driven wellness optimization.
How much funding has Cymbiotika raised?
Cymbiotika has raised a total of $55.1M across 3 funding rounds:
Debt
$68K
Debt
$30M
Seed
$25M
Debt (2021): $68K with participation from PPP
Debt (2024): $30M led by RevTek Capital
Seed (2025): $25M, investors not publicly disclosed
Key Investors in Cymbiotika
RevTek Capital
RevTek Capital is a specialized financial firm focused on providing growth-oriented debt solutions to emerging companies with recurring revenue models. They are known for their operational expertise and ability to provide non-dilutive capital that supports long-term business scaling.
PPP
Public-Private Partnership
Undisclosed Investor
A strategic partner participating in the most recent funding round to support the company's next phase of enterprise-level growth.
What's next for Cymbiotika?
With the recent influx of capital, Cymbiotika is poised to transition into a more aggressive phase of enterprise-level scaling. The strategic roadmap likely involves expanding its product portfolio to include advanced pet health solutions and enhancing its digital infrastructure to support a more personalized user experience. As the company moves beyond its historical reliance on debt-based financing, this new equity-focused backing provides the necessary liquidity to invest in supply chain resilience and broader market acquisition. Investors will be watching closely to see how the firm leverages this liquidity to maintain its competitive edge against emerging wellness brands while scaling its subscription ecosystem.
See full Cymbiotika company page
